Hypersensitivity of nonhomologous DNA end-joining mutants to VP-16 and ICRF-193: implications for the repair of topoisomerase II-mediated DNA damage - PubMed (original) (raw)
. 2003 Sep 19;278(38):35897-902.
doi: 10.1074/jbc.M306500200. Epub 2003 Jul 3.
Affiliations
- PMID: 12842886
- DOI: 10.1074/jbc.M306500200
Free article
Hypersensitivity of nonhomologous DNA end-joining mutants to VP-16 and ICRF-193: implications for the repair of topoisomerase II-mediated DNA damage
Noritaka Adachi et al. J Biol Chem. 2003.
Free article
Abstract
A number of clinically useful anticancer drugs, including etoposide (VP-16), target DNA topoisomerase (topo) II. These drugs, referred to as topo II poisons, stabilize cleavable complexes, thereby generating DNA double-strand breaks. Bis-2,6-dioxopiperazines such as ICRF-193 also inhibit topo II by inducing a distinct type of DNA damage, termed topo II clamps, which has been believed to be devoid of double-strand breaks. Despite the biological and clinical importance, the molecular mechanisms for the repair of topo II-mediated DNA damage remain largely unknown. Here, we perform genetic analyses using the chicken DT40 cell line to investigate how DNA lesions caused by topo II inhibitors are repaired. Notably, we show that LIG4-/- and KU70-/- cells, which are defective in nonhomologous DNA end-joining (NHEJ), are extremely sensitive to both VP-16 and ICRF-193. In contrast, RAD54-/- cells (defective in homologous recombination) are much less hypersensitive to VP-16 than the NHEJ mutants and, more importantly, are not hypersensitive to ICRF-193. Our results provide the first evidence that NHEJ is the predominant pathway for the repair of topo II-mediated DNA damage; that is, cleavable complexes and topo II clamps. The outstandingly increased cytotoxicity of topo II inhibitors in the absence of NHEJ suggests that simultaneous inhibition of topo II and NHEJ would provide a powerful protocol in cancer chemotherapy involving topo II inhibitors.
Similar articles
- Genetic evidence for involvement of two distinct nonhomologous end-joining pathways in repair of topoisomerase II-mediated DNA damage.
Adachi N, Iiizumi S, So S, Koyama H. Adachi N, et al. Biochem Biophys Res Commun. 2004 Jun 11;318(4):856-61. doi: 10.1016/j.bbrc.2004.04.099. Biochem Biophys Res Commun. 2004. PMID: 15147950 - Roles of nonhomologous end-joining pathways in surviving topoisomerase II-mediated DNA damage.
Malik M, Nitiss KC, Enriquez-Rios V, Nitiss JL. Malik M, et al. Mol Cancer Ther. 2006 Jun;5(6):1405-14. doi: 10.1158/1535-7163.MCT-05-0263. Mol Cancer Ther. 2006. PMID: 16818498 - Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M, Wessel I, Jensen LH, Holm B, Oliveri RS, Kenwrick S, Creighton AM, Nitiss JL, Jensen PB. Sehested M, et al. Cancer Res. 1998 Apr 1;58(7):1460-8. Cancer Res. 1998. PMID: 9537249 - DNA topoisomerase II rescue by catalytic inhibitors: a new strategy to improve the antitumor selectivity of etoposide.
Jensen PB, Sehested M. Jensen PB, et al. Biochem Pharmacol. 1997 Oct 1;54(7):755-9. doi: 10.1016/s0006-2952(97)00116-0. Biochem Pharmacol. 1997. PMID: 9353129 Review. - Recent advances in the development of dual topoisomerase I and II inhibitors as anticancer drugs.
Salerno S, Da Settimo F, Taliani S, Simorini F, La Motta C, Fornaciari G, Marini AM. Salerno S, et al. Curr Med Chem. 2010;17(35):4270-90. doi: 10.2174/092986710793361252. Curr Med Chem. 2010. PMID: 20939813 Review.
Cited by
- A Cell System-Assisted Strategy for Evaluating the Natural Antioxidant-Induced Double-Stranded DNA Break (DSB) Style.
Someya Y, Kobayashi S, Toriumi K, Takeda S, Adachi N, Kurosawa A. Someya Y, et al. Genes (Basel). 2023 Feb 6;14(2):420. doi: 10.3390/genes14020420. Genes (Basel). 2023. PMID: 36833347 Free PMC article. - PD-1/PD-L1 and DNA Damage Response in Cancer.
Kciuk M, Kołat D, Kałuzińska-Kołat Ż, Gawrysiak M, Drozda R, Celik I, Kontek R. Kciuk M, et al. Cells. 2023 Feb 7;12(4):530. doi: 10.3390/cells12040530. Cells. 2023. PMID: 36831197 Free PMC article. Review. - Investigating the Anticancer Potential of Salvicine as a Modulator of Topoisomerase II and ROS Signaling Cascade.
Dey D, Hasan MM, Biswas P, Papadakos SP, Rayan RA, Tasnim S, Bilal M, Islam MJ, Arshe FA, Arshad EM, Farzana M, Rahaman TI, Baral SK, Paul P, Bibi S, Rahman MA, Kim B. Dey D, et al. Front Oncol. 2022 Jun 1;12:899009. doi: 10.3389/fonc.2022.899009. eCollection 2022. Front Oncol. 2022. PMID: 35719997 Free PMC article. Review. - RIF1-ASF1-mediated high-order chromatin structure safeguards genome integrity.
Feng S, Ma S, Li K, Gao S, Ning S, Shang J, Guo R, Chen Y, Blumenfeld B, Simon I, Li Q, Guo R, Xu D. Feng S, et al. Nat Commun. 2022 Feb 17;13(1):957. doi: 10.1038/s41467-022-28588-y. Nat Commun. 2022. PMID: 35177609 Free PMC article. - Diversity upon diversity: linking DNA double-strand break repair to blood cancer health disparities.
Sterrenberg JN, Folkerts ML, Rangel V, Lee SE, Pannunzio NR. Sterrenberg JN, et al. Trends Cancer. 2022 Apr;8(4):328-343. doi: 10.1016/j.trecan.2022.01.003. Epub 2022 Jan 31. Trends Cancer. 2022. PMID: 35094960 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous